Tracking brain wave signatures could reduce the risk of postoperative brain dysfunction

Ab­b­Vie is jump­ing in­to the TL1A space, ink­ing a new deal with a Bei­jing-based biotech. The com­pa­ny said Thurs­day that it’s part­ner­ing with Fu­ture­Gen Bio­phar­ma­ceu­ti­cal

Plus, news about Telios Phar­ma and Celldex Ther­a­peu­tics: An­oth­er day, an­oth­er pub­lic of­fer­ing: Apogee Ther­a­peu­tics is aim­ing to raise $350 mil­lion in a stock sale